VERONA PHARMA PLC - ADR (VRNA)

Verona Pharma Announces December 2024 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior...

Verona Pharma to Present at Jefferies London Healthcare Conference

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior...

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique...

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024. ...

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024....

First Week of VRNA October 18th Options Trading

VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024.

VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Verona Pharma (NASDAQ:VRNA) just reported results for the second quarter of 202...

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference...

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior...

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Verona Pharma announces the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients. ...

Verona Pharma (VRNA) Shares Cross Above 200 DMA

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

The companies are closing in on the finish line for two new COPD treatments.

RSI Alert: Verona Pharma (VRNA) Now Oversold

VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024

VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024.

VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Verona Pharma (NASDAQ:VRNA) just reported results for the first quarter of 2024...

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and...

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma plc to present additional analyses of positive Phase 3 ENHANCE studies in COPD at ATS 2024. ...

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team....

3 Healthcare Stocks That Have Outperformed Nvidia Since 2022

The healthcare sector is no slouch when it comes to top-performing growth stocks.

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and...

Bullish Two Hundred Day Moving Average Cross - VRNA

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...

Michael Austwick Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today...